Premium
DIVERSOMER TM technology: Solid phase synthesis, automation, and integration for the generation of chemical diversity
Author(s) -
Dewitt Sheila Hobbs,
Schroeder Mel C.,
Stankovic Charles J.,
Strode John E.,
Czarnik Anthony W.
Publication year - 1994
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430330208
Subject(s) - automation , drug discovery , organic synthesis , combinatorial chemistry , solid phase synthesis , organic molecules , computer science , nanotechnology , process (computing) , chemical synthesis , drug development , chemistry , drug , process engineering , biochemical engineering , materials science , molecule , organic chemistry , engineering , pharmacology , medicine , biochemistry , mechanical engineering , peptide , operating system , catalysis , in vitro
The drug discovery process depends upon the synthesis and testing of thousands of compounds to bring a new drug through discovery, clinical testing, development, and FDA approval. Recent advances in high throughput screening have created the need for the accelerated synthesis of small organic molecules. By combining solid phase chemistry, organic synthesis, and automation with a unique apparatus capable of performing techniques common to organic synthesis, “libraries” of organic compounds (DIVERSOMERS TM ) are efficiently generated. This was demonstrated by the multiple simultaneous synthesis of 40 hydantoins and 40 benzodiazepines, related to Dilantin® and Valium®, respectively. © 1994 Wiley‐Less, Inc.